Antipsychotic medication and long-term mortality risk in patients with schizophrenia; A systematic review and meta-analysis

Psychological Medicine

Volumn 47, Issue 13, 2017, Pages 2217-2228

  Vermeulen, J ^a   Van Rooijen, G ^a   Doedens, P ^a   Numminen, E ^a   Van Tricht, M ^a   De Haan, L ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Antipsychotics; meta analysis; mortality; schizophrenia

Indexed keywords

NEUROLEPTIC AGENT;

HUMAN; META ANALYSIS; MORTALITY; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; HUMANS; SCHIZOPHRENIA;

EID: 85017476098     PISSN: 00332917     EISSN: 14698978     Source Type: Journal    
DOI: 10.1017/S0033291717000873     Document Type: Article

References (46)

1. Alphs L, Benson C, Cheshire-Kinney K, Lindenmayer J, Mao L, Rodriguez S, Starr H (2015). Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review board-blinded 15-month study. Journal of Clinical Psychiatry 76, 554-561.
2. Borenstein M, Hedges L, Higgins J, Rothstein H (2009). Introduction to Meta-Analysis. John Wiley & Sons Ltd: Chichester, UK.
3. Bushe C, Taylor M, Haukka J (2010). Mortality in schizophrenia: a measurable clinical endpoint. Journal of Psychopharmacology 24, 17-25.
4. Chen V, Liao Y, Lai T, Lane H, ShaoW, Dewey M, Lee C, Lu M (2015). Survival analysis of the use of first and second generation antipsychotics among patients suffering schizophrenia: a nationwide population-based cohort study. Schizophrenia Research 169, 406-411.
5. Copeland L, Zeber J, Wang C, Parchman M, Lawrence V, Valenstein M, Miller A (2009). Patterns of primary care and mortality among patients with schizophrenia or diabetes: a cluster analysis approach to the retrospective study of healthcare utilization. BMC Health Services Research 9, 127.
6. Correll C, Detraux J, De Lepeleire J, De Hert M (2015). Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World psychiatry 14, 119-136.
7. Cullen B, McGinty E, Zhang Y, Dosreis S, Steinwachs D, Guallar E, Daumit G (2013). Guideline-concordant antipsychotic use and mortality in schizophrenia. Schizophrenia Bulletin 39, 1159-1168.
8. de Arce Cordon R, Eding E, Marques-Teixeira J, Milanova V, Rancans E, Schreiner A (2012). Descriptive analyses of the aripiprazole arm in the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE). European Archives of Psychiatry and Clinical Neuroscience 262, 139-149.
9. De Hert M, Correll C, Cohen D (2010). Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study. Schizophrenia Research 117, 68-74.
10. De Hert M, Detraux J, vanWinkel R, YuW, Correll C (2012). Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nature Reviews Endocrinology 8, 114-126.
11. Deslandes P, Dwivedi M, Sewell R (2015). Five-year patient outcomes with risperidone long-acting injection or oral aripiprazole. Therapeutic Advances in Psychopharmacology 5, 151-157.
12. Gaebel W, Bergmans P, De Arce R, Rouillon F, Cordes J, Eriksson L, Schreiner A, Smeraldi E (2010). Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial. Neuropsychopharmacology 35, 2367-2377.
13. Girgis R, Phillips M, Li X, Li K, Jiang H, Wu C, Duan N, Niu Y, Lieberman J (2011). Clozapine v. chlorpromazine in treatment-naive, first-episode schizophrenia: 9-year outcomes of a randomised clinical trial. British Journal of Psychiatry 199, 281-288.
14. Haukka J, Tiihonen J, Harkanen T, Lonnqvist J (2008). Association between medication and risk of suicide, attempted suicide and death in nationwide cohort of suicidal patients with schizophrenia. Pharmacoepidemiology and Drug Safety 17, 686-696.
15. Hayes R, Downs J, Chang C, Jackson R, Shetty H, Broadbent M, Hotopf M, Stewart R (2015). The effect of clozapine on premature mortality: an assessment of clinical monitoring and other potential confounders. Schizophrenia Bulletin 41, 644-655.
16. Higgins J, Altman D, Gotzsche P, Juni P, Moher D, Oxman A, Savovic J, Schulz K, Weeks L, Sterne J, Cochrane Bias Methods Group & Cochrane Statistical Methods Group (2011). TheCochrane Collaboration's tool for assessing risk of bias in randomised trials. British Medical Journal 343, d5928.
17. Higgins J, Thompson S, Deeks J, Altman D (2003). Measuring inconsistency in meta-analyses. British Medical Journal 327, 557-560.
18. Horwitz R, Viscoli C, Clemens J, Sadock R (1990). Developing improved observational methods for evaluating therapeutic effectiveness. American Journal of Medicine 89, 630-638.
19. Kasper S, Moller H, Hale A (2010). The European post-marketing observational Sertindole study: an investigation of the safety of antipsychotic drug treatment. European Archives of Psychiatry and Clinical Neuroscience 260, 59-68.
20. Kelly D, McMahon R, Liu F, Love R, Wehring H, Shim J, Warren K, Conley R (2010). Cardiovascular disease mortality in patients with chronics schizophrenia treated with clozapine: a retrospective cohort study. Journal of Clinical Psychiatry 71, 304-311.
21. Khan A, Faucett J, Morrison S, Brown W (2013). Comparative mortality risk in adult patients with schizophrenia, depression, bipolar disorder, anxiety disorders, and attention-deficit/hyperactivity disorder participating in psychopharmacology clinical trials. JAMA Psychiatry 70, 1091-1099.
22. Khan A, Schwartz K, Stern C, Redding N, Kolts R, Brown W, Robinson D (2007). Mortality risk in patients with schizophrenia participating in premarketing atypical antipsychotic clinical trials. Journal of Clinical Psychiatry 68, 1828-1833.
23. Leucht S, Burkard T, Henderson J, Maj M, Sartorius N (2007). Physical illness and schizophrenia: a review of the literature. Acta Psychiatrica Scandinavica 116, 317-333.
24. Levesque L, Hanley J, Kezouh A, Suissa S (2010). Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. British Medical Journal 340, b5087.
25. Lieberman J, Stroup T, McEvoy J, Swartz M, Rosenheck R, Perkins D, Keefe R, Davis S, Davis C, Lebowitz B, Severe J, Hsiao J, Clinical Antipsychotic Trials of Intervention Effectiveness Investigators (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353, 1209-1223.
26. Meltzer H, Alphs L, Green A, Altamura A, Anand R, Bertoldi A, Bourgeois M, Chouinard G, Islam M, Kane J, Krishnan R, Lindenmayer J, Potkin S, International Suicide Prevention Trial Study Group (2003). Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Archives of General Psychiatry 60, 82-91.
27. Moher D, Liberati A, Tetzlaff J, Altman D, Prisma Group (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine 6, e1000097.
28. Montout C, Casadebaig F, Lagnaoui R, Verdoux H, Philippe A, Begaud B, Moore N (2002). Neuroleptics and mortality in schizophrenia: prospective analysis of deaths in a French cohort of schizophrenic patients. Schizophrenia Research 57, 147-156.
29. Olfson M, Gerhard T, Huang C, Crystal S, Stroup T (2015). Premature mortality among adults with schizophrenia in the United States. JAMA Psychiatry 72, 1172-1181.
30. Osborn D, Levy G, Nazareth I, Petersen I, Islam A, King M (2007). Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Rsearch Database. Archives of General Psychiatry 64, 242-249.
31. Pocock S, Elbourne D (2000). Randomized trials or observational tribulations? New England Journal of Medicine 342, 1907-1909.
32. Pridan S, Baruch Y, Swartz M, Barak Y (2014). Amisulpride for older patients with long-standing schizophrenia. Journal of Clinical Psychopharmacology 34, 736-737.
33. Ran M, Weng X, Chan C, Chen E, Tang C, Lin F, MaoW, Hu S, Huang Y, Xiang M (2015). Different outcomes of never-treated and treated patients with schizophrenia: 14-year follow-up study in rural China. British Journal of Psychiatry 207, 495-500.
34. Ritchie C, Harrigan S, Mastwyk M, Macfarlane S, Cheesman N, Ames D (2010). Predictors of adherence to atypical antipsychotics (risperidone or olanzapine) in older patients with schizophrenia: an open study of 3(1/2) years duration. International Journal of Geriatric Psychiatry 25, 411-418.
35. Saha S, Chant D, McGrath J (2007). A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Archives of General Psychiatry 64, 1123-1131.
36. Sernyak M, Desai R, Stolar M, Rosenheck R (2001). Impact of clozapine on completed suicide. American Journal of Psychiatry 158, 931-937.
37. Tandon R, Nasrallah H, Keshavan M (2010). Schizophrenia, 'Just the Facts' 5. Treatment and prevention Past, present, and future. Schizophrenia Research 122, 1-23.
38. TaylorD, Douglas-Hall P, OlofinjanaB, Whiskey E, ThomasA (2009). Reasons for discontinuing clozapine: matched, case-control comparison with risperidone long-acting injection. British Journal of Psychiatry 194, 165-167.
39. Tenback D, Fiji B, Smeets H, van Os J, van Harten P (2012). All-cause mortality and medication risk factors in schizophrenia: a prospective cohort study. Journal of Clinical Psychopharmacology 32, 31-35.
40. Thomas S, Drici M, Hall G, Crocq M, Everitt B, Lader M, Le Jeunne C, Naber D, Priori S, Sturkenboom M, Thibaut F, Peuskens J, Mittoux A, Tanghoj P, Toumi M, Moore N, Mann R (2010). Safety of sertindole versus risperidone in schizophrenia: principal results of the sertindole cohort prospective study (SCoP). Acta Psychiatrica Scandinavica 122, 345-355.
41. Tiihonen J, Lonnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, Haukka J (2009). 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 374, 620-627.
42. Tiihonen J, Wahlbeck K, Lonnqvist J, Klaukka T, Ioannidis J, Volavka J, Haukka J (2006). Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. British Medical Journal 333, 224.
43. Torniainen M, Mittendorfer-Rutz E, Tanskanen A, Bjorkenstam C, Suvisaari J, Alexanderson K, Tiihonen J (2015). Antipsychotic treatment and mortality in schizophrenia. Schizophrenia Bulletin 41, 656-663.
44. Walker E, McGee R, Druss B (2015). Mortality in mental disorders andglobal disease burden implications: a systematic review and meta-analysis. JAMA Psychiatry 72, 334-341.
45. Weinmann S, Read J, Aderhold V (2009). Influence of antipsychotics on mortality in schizophrenia: systematic review. Schizophrenia Research 113, 1-11.
46. Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M. The Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomised studies in meta-analyses http://www. ohri. ca/programs/clinical-epidemiology/oxford. asp.